These findings have been replicated in non-human primate models of PD with dyskinetic monkeys receiving a combination of 5-HT1A and 5-HT1B agonists displaying an 80% reduction of dyskinesias without a significant worsening of their parkinsonian scores compared to L-Dopa-only treated animals (Munoz et al., 2008). Here, HTR1B is linked to Parkinson disease.